ICD-11 code 2C61.2 represents invasive pleomorphic lobular carcinoma of the breast. This particular type of breast cancer is characterized by abnormal cells that invade the surrounding tissue. Pleomorphic lobular carcinoma is a rare and aggressive form of breast cancer that typically affects older women, particularly those postmenopausal.
Invasive pleomorphic lobular carcinoma of the breast is often difficult to detect using traditional screening methods, making early diagnosis crucial for successful treatment. This type of cancer is known for its distinct histological features, including large, pleomorphic, and atypical cells. Treatment options for invasive pleomorphic lobular carcinoma typically involve a combination of surgery, chemotherapy, radiation therapy, and hormonal therapy.
Table of Contents:
- #️⃣ Coding Considerations
- 🔎 Symptoms
- 🩺 Diagnosis
- 💊 Treatment & Recovery
- 🌎 Prevalence & Risk
- 😷 Prevention
- 🦠 Similar Diseases
#️⃣ Coding Considerations
In the SNOMED CT terminology system, the equivalent code for the ICD-11 code 2C61.2, which represents invasive pleomorphic lobular carcinoma of the breast, is 611721000000108. This code is used to classify the specific type of breast cancer characterized by abnormal cells forming in the lobules of the breast, which can spread to other tissues. By using this standardized code, healthcare professionals can accurately document and track cases of invasive pleomorphic lobular carcinoma across different medical settings. This ensures consistency in reporting and data analysis, ultimately improving the quality of care for patients with this type of breast cancer. With the increasing emphasis on interoperability and electronic health records, having a clear and precise coding system like SNOMED CT is essential for efficient communication and decision-making in healthcare.
In the United States, ICD-11 is not yet in use. The U.S. is currently using ICD-10-CM (Clinical Modification), which has been adapted from the WHO’s ICD-10 to better suit the American healthcare system’s requirements for billing and clinical purposes. The Centers for Medicare and Medicaid Services (CMS) have not yet set a specific date for the transition to ICD-11.
The situation in Europe varies by country. Some European nations are considering the adoption of ICD-11 or are in various stages of planning and pilot studies. However, as with the U.S., full implementation may take several years due to similar requirements for system updates and training.
🔎 Symptoms
Symptoms of 2C61.2 (Invasive pleomorphic lobular carcinoma of breast) may vary among individuals. However, common manifestations of this type of breast cancer can include a palpable lump or thickening in the breast tissue. This lump may feel hard, irregular in shape, and may be fixed to the surrounding tissue. Patients may also experience changes in the skin overlying the affected area, such as redness, dimpling, or puckering.
In some cases, individuals with invasive pleomorphic lobular carcinoma may notice changes in the appearance of their nipple, such as inversion or discharge. Additionally, pain or tenderness in the breast, especially in the absence of a traumatic injury, may be indicative of this form of breast cancer. It is important to note that symptoms can vary among patients, and some individuals may not experience any noticeable changes in their breast despite having invasive pleomorphic lobular carcinoma.
Due to the nature of invasive pleomorphic lobular carcinoma, the tumor cells can infiltrate the surrounding breast tissue and potentially spread to nearby lymph nodes. This dissemination can lead to symptoms such as swelling or enlargement of the lymph nodes in the axilla (armpit) or supraclavicular region. Patients may also experience a sensation of heaviness or fullness in the affected breast, as well as discomfort or pain in the area. However, it is crucial to consult a healthcare provider for a proper evaluation and diagnosis if any concerning symptoms arise.
🩺 Diagnosis
Diagnosis of invasive pleomorphic lobular carcinoma of the breast, coded as 2C61.2, typically begins with a physical examination and review of the patient’s medical history. Doctors may perform imaging tests such as mammograms, ultrasound, or magnetic resonance imaging (MRI) to examine the breast tissue for any abnormalities. Additionally, a biopsy is often required to confirm the presence of cancerous cells in the breast.
During a biopsy, a small sample of tissue is removed from the suspicious area in the breast and examined under a microscope by a pathologist. This allows for a definitive diagnosis of invasive pleomorphic lobular carcinoma based on the characteristics of the cancer cells. The pathologist may also conduct additional tests, such as hormone receptor testing, to determine the specific subtype of breast cancer present.
Once a diagnosis of invasive pleomorphic lobular carcinoma is confirmed, further staging tests may be recommended to assess the extent of the cancer and determine the best course of treatment. These tests may include blood tests, imaging scans, and possibly a bone marrow biopsy to look for any signs of cancer spread. The results of these tests help doctors develop a treatment plan tailored to the individual patient’s needs and ensure the most effective course of action.
💊 Treatment & Recovery
Treatment and recovery methods for invasive pleomorphic lobular carcinoma of the breast (2C61.2) typically involve a combination of surgery, radiation therapy, chemotherapy, targeted therapy, and hormone therapy. Surgery is often the initial step in treating this type of cancer, with the goal of removing as much of the tumor as possible. This may involve a lumpectomy or mastectomy, depending on the size and location of the tumor.
Following surgery, patients may undergo radiation therapy to destroy any remaining cancer cells in the breast or surrounding tissue. This treatment is typically administered daily over the course of several weeks. Chemotherapy may also be recommended to help kill cancer cells that may have spread to other parts of the body. This treatment involves the use of powerful medications that are delivered either intravenously or orally.
In some cases, targeted therapy may be used to treat invasive pleomorphic lobular carcinoma of the breast. This type of treatment targets specific proteins or genes that are present in cancer cells, helping to stop the growth and spread of the disease. Hormone therapy may also be used, particularly if the cancer is hormone receptor-positive. This treatment works by blocking the effects of estrogen or progesterone, which can fuel the growth of certain types of breast cancer. It is important for patients to work closely with their healthcare team to determine the most appropriate treatment plan for their individual case.
🌎 Prevalence & Risk
In the United States, invasive pleomorphic lobular carcinoma of the breast, coded as 2C61.2 in the International Classification of Diseases, has been reported to account for approximately 10-15% of all invasive lobular breast carcinomas. This subtype of breast cancer is less common than invasive ductal carcinoma, but studies have shown that it tends to present at a higher grade and with more aggressive characteristics.
In Europe, the prevalence of 2C61.2 varies across different countries and regions. Studies have suggested that invasive pleomorphic lobular carcinoma of the breast may be more common in some European countries compared to others. However, overall, the incidence of this subtype of breast cancer is lower than that of invasive ductal carcinoma.
In Asia, the prevalence of invasive pleomorphic lobular carcinoma of the breast, represented by the code 2C61.2, has been reported to be lower compared to Western countries. Studies have shown that this subtype of breast cancer tends to occur less frequently in Asian populations, with a lower proportion of cases diagnosed as pleomorphic lobular carcinoma.
In Australia, the prevalence of invasive pleomorphic lobular carcinoma of the breast, coded as 2C61.2, is not well-documented in the literature. However, studies have suggested that this subtype of breast cancer may be less common compared to invasive ductal carcinoma in Australian populations. Further research is needed to better understand the prevalence and characteristics of invasive pleomorphic lobular carcinoma of the breast in Australia.
😷 Prevention
To prevent 2C61.2 (Invasive pleomorphic lobular carcinoma of the breast), it is important to maintain a healthy lifestyle and participate in regular breast cancer screenings. Early detection is key in preventing the spread of the disease, so women should undergo routine mammograms as recommended by their healthcare provider. Additionally, conducting self-breast exams on a monthly basis can help women become familiar with their breast tissue and notice any changes that may indicate a potential issue.
Eating a balanced diet rich in fruits, vegetables, whole grains, and lean proteins can also play a role in preventing invasive pleomorphic lobular carcinoma. Maintaining a healthy weight and limiting the consumption of alcohol and processed foods can decrease the risk of developing breast cancer. Regular exercise is another important factor in prevention, as physical activity has been shown to reduce the risk of various types of cancer, including breast cancer.
Lastly, women with a family history of breast cancer or those with known genetic mutations that increase the risk of the disease should consult with a genetic counselor to discuss options for preventive measures. Some women may benefit from undergoing genetic testing to determine their risk level and make informed decisions about their healthcare. By taking proactive steps to reduce risk factors and prioritize breast health, individuals can help prevent 2C61.2 and other forms of invasive lobular carcinoma.
🦠 Similar Diseases
Firstly, one disease similar to 2C61.2 is invasive ductal carcinoma of the breast (C50.9). This type of breast cancer originates in the milk ducts and is the most common form of breast cancer. It is characterized by the abnormal growth of cells that invade surrounding tissues and may spread to other parts of the body.
Another related disease to 2C61.2 is invasive lobular carcinoma of the breast (C50.8). This type of breast cancer begins in the lobules, or milk-producing glands, of the breast. It is less common than invasive ductal carcinoma but has similar characteristics in terms of invasiveness and potential for metastasis.
Additionally, Paget’s disease of the breast (D05.01) is a related condition to 2C61.2. This disease typically starts in the ducts of the nipple and spreads to the surrounding skin. It may present as a scaly or eczema-like rash on the nipple and can indicate an underlying breast cancer, such as invasive pleomorphic lobular carcinoma.